31.08.2013 Views

Experimental infection and protection against ... - TI Pharma

Experimental infection and protection against ... - TI Pharma

Experimental infection and protection against ... - TI Pharma

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Humoral immune responses to a single allele PfAMA1 vaccine in healthy malarianaïve<br />

adults.<br />

Fraction of IgG remaining (%)<br />

100<br />

80<br />

60<br />

40<br />

20<br />

0<br />

100<br />

80<br />

60<br />

40<br />

20<br />

0<br />

100<br />

80<br />

60<br />

40<br />

20<br />

0<br />

0<br />

0.14<br />

0.41<br />

Alhydrogel 10 Alhydrogel 50<br />

ISA 720 10 ISA 720 50<br />

AS02 10 AS02 50<br />

1.23<br />

3.7<br />

11.11<br />

33.33<br />

100<br />

0<br />

Competitor concentration (µg/mL)<br />

Figure 3. Competition ELISA using four different competitor antigens on FVO coated<br />

plates in serum obtained on day 84.<br />

Concentration of competitor antigen is depicted on the x-axis (µg /ml) <strong>and</strong> the fraction<br />

remaining bound to the ELISA plate is depicted on the y-axis (%). Light Blue = FVO AMA1<br />

(homologous), Orange = HB3 AMA1, Green = CAMP AMA1 <strong>and</strong> Dark Blue = 3D7 AMA1.<br />

Treatment groups are indicated by Adjuvant name <strong>and</strong> AMA1 dose, respectively.<br />

0.14<br />

0.41<br />

1.23<br />

3.7<br />

11.11<br />

33.33<br />

100<br />

65

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!